Thyreogen
A-2, thyroid peptide bioregulator
Thyreogen (A-2, thyroid peptide bioregulator) is a longevity & bioregulators research compound. Thyroid-derived peptide fraction. Khavinson-school organ peptide extracts. The claim is tissue specificity: a short peptide fraction from one organ is proposed to act on that same organ, restoring its protein synthesis toward a younger pattern by binding regulatory DNA sequences. The mechanism is coherent and the human evidence for it is thin outside the group that proposed it. Note this is a tissue extract, NOT thyroid hormone and not a substitute for it.
Thyreogen quick facts
| Reported research dose | 40-160mg daily (1-2 capsules, 1-2x daily with food · 40mg/capsule) |
| Route | Oral |
| Frequency | 1-2x Daily · Daily during a course |
| Half-life | Not characterized |
| Forms | Oral |
| Evidence level | Theoretical — Khavinson-school work, largely Russian-language and rarely replicated outside it |
The Khavinson literature behind this is decades deep, almost entirely Russian-language, and rarely replicated by any independent group — small single-arm series rather than controlled trials. Absence of replication is not evidence it fails; it is an absence of the evidence that would settle it either way. Dose and course length follow the manufacturer's convention, not a trial. Not a thyroid hormone. Anyone with diagnosed thyroid disease should be reasoning about T4/T3 and TSH with a clinician, not about this. Thyroid-directed. Worth being clear that this is not thyroid hormone and will not act like it. Course pattern: roughly 10 days on, then off, once or twice a year. To know whether it did anything, a full panel — TSH, free T3, free T4 — not TSH alone. Run it as an experiment you measure, not a protocol you trust.
How Thyreogen works
Thyroid-derived peptide fraction. Khavinson-school organ peptide extracts. The claim is tissue specificity: a short peptide fraction from one organ is proposed to act on that same organ, restoring its protein synthesis toward a younger pattern by binding regulatory DNA sequences. The mechanism is coherent and the human evidence for it is thin outside the group that proposed it. Note this is a tissue extract, NOT thyroid hormone and not a substitute for it.
Proposed benefits
Thyroid tissue support — and it is NOT thyroid hormone, which is what actually treats hypothyroidism.
Where to get Thyreogen
Buy Thyreogen at BioLongevity Supplements →The evidence for Thyreogen
Graded by what exists behind each claim.
Human clinical evidence
- No randomized human trials — a research compound with no commercial route to funding one, so the correlative and theoretical tiers are the evidence base rather than a consolation prize.
📊 Correlative data
- The Khavinson group reported improvements in organ-specific markers across a long series of studies from the 1980s onward. These are overwhelmingly small, single-arm, and published in Russian-language journals; independent replication outside that school is close to absent.
🧪 How the mechanism reads
- The proposal is tissue specificity: a short peptide fraction taken from one organ acts preferentially on that same organ, binding regulatory DNA sequences and shifting protein synthesis toward a younger pattern. It is a coherent mechanism and it is why these are dosed as short courses rather than continuously.
- Oral delivery is the open question, not the mechanism. Peptides are poorly absorbed intact from the gut, which is why the oral capsules run 10-20x the injectable milligram dose. Whether enough survives to reach the target tissue has not been shown in a way anyone outside the manufacturer can check.
Why an empty tier is not a verdict →
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Thyreogen actually does
Thyreogen is a thyroid-derived peptide complex in capsules, and it is the one product in this catalog with a safety question that its own source tissue creates. Hold that thought for 3 paragraphs; it is the most important thing on this page and it needs the mechanism first.
What a complex is, and what it is not. This is not a molecule with a sequence, so there is no isoelectric point to compute and no half-life to predict. It is what remains after thyroid tissue is extracted and size-fractionated, standardized by total peptide content. There is no formula, no exact mass, no isoelectric point, no computable charge — none of the numbers that make the defined peptides in this catalog arguable. Cardiogen is C18H31N7O9 at 489.50 Da; Chonluten is C11H17N3O8 at 319.28 Da. Both can be checked against a vial. Nothing here can.
The delivery argument, which this product cannot make. The route into an epithelial cell proposed by this school is the proton-coupled oligopeptide transporter PEPT1, with a described substrate range of di- and tripeptides — 2 and 3 residues Khavinson 2022. A capsule taken with food faces gastric acid, pancreatic proteases and brush-border peptidases first, and then hepatic first-pass extraction after. The thyroid sits behind all of that, so a swallowed preparation aimed at it has to survive hepatic first-pass clearance and be delivered by blood rather than acting on contact. With no published size distribution for the mixture, there is no way to say whether it contains anything the named carrier could take. The transcriptional claim behind the class Khavinson 2021 and the structural work on how a short peptide could recognize a DNA sequence at all Kolchina 2019 are both about defined molecules, and neither can be applied to an undefined one.
Now the thing nobody says. This preparation is made from thyroid tissue, and thyroid tissue is where thyroid hormone is stored — T4 and T3 held on thyroglobulin, in colloid, in quantities that are pharmacologically enormous relative to a capsule. Thyroid hormones are small iodinated amino-acid derivatives, not peptides: they are heat-stable, acid-stable, protease-resistant and orally active, which is precisely why levothyroxine works as a tablet. Any extraction step that removes peptides from thyroid tissue has no obvious reason to remove thyroid hormone with them, and no vendor of this product publishes an assay showing that it did. That is not an accusation. It is a gap, it is specific to this product among the 12 organ preparations on this site, and there is a 1-line blood test that closes it.
Cell, rodent, human — and where it stops
The count. Nothing is indexed under this trade name. A PubMed-restricted search across the oral organ-extract line on this site returns 1 record between 4 of the products, and it concerns bladder function rather than thyroid. For Thyreogen specifically: 0 randomized trials, 0 controlled trials, 0 animal studies, 0 mechanism papers.
What the class contributes and what it cannot. The human record most often invoked for this family is the elderly series in which thymus and pineal preparations were injected over 6 to 8 years Khavinson 2003 — 2 named preparations, a different route, different organs. The independent outside view is a systematic review pooling 24 randomized trials over 2,245 participants, with risk of bias moderate to high and certainty of evidence low to very low, on cognitive endpoints Alsulaimani 2021. Neither says anything about thyroid tissue, and neither was generated with an oral extract.
The obstacle here is unusual, because the target organ is the most measurable one in the body. For most compounds in this catalog the complaint is that no marker exists. The thyroid axis is the opposite: TSH, free T4, free T3 and thyroid antibodies are cheap, standardized, widely available and interpreted by a well-established logic. TSH in particular responds to free T4 on a log scale, which makes it one of the most sensitive endocrine assays in medicine. So the reason there is no evidence for this product is not that the evidence would be hard to collect. It is that nobody has collected it, and that is a much less forgivable gap than it is on the pages where the readout genuinely does not exist.
And the comparator is unusually strong. Hypothyroidism has a treatment that is titrated to a number, costs almost nothing, and is among the most-prescribed drugs in the world. This product has 0 human studies. Whatever the peptide hypothesis is worth, it is not competing against nothing.
Thyreogen pharmacokinetics — how much of it actually gets in
‘Not characterized’ is accurate. Here is the reasoning that should follow it.
What degrades it. A mixture has 1 clearance curve per component, so no single half-life could be correct even in principle. Any short peptide that reached plasma would meet aminopeptidases and be trimmed from its termini within minutes; anything longer would meet endopeptidases first. Before that, a swallowed capsule meets pepsin at gastric pH and then pancreatic proteases and brush-border peptidases in the small intestine, which is a 3-stage proteolytic filter designed by evolution to reduce dietary protein to amino acids and di-/tripeptides.
The oral barrier, and the arithmetic the blank was hiding. The one named route across the enterocyte is PEPT1, carrying 2- and 3-residue peptides Khavinson 2022; anything crossing then faces hepatic first-pass extraction. No oral bioavailability figure has been published for this preparation or for any product in this family. Bound it rather than guess: even at a generous 1 in 10 surviving, an oral course and the subcutaneous courses elsewhere in this catalog would differ about 10x in delivered material, and nothing published could tell a 10x gap from a 1,000x one. What can be said is the shape of the problem: the fraction surviving is unmeasured, the mechanism gives no reason to expect it to be large, and the product is dosed daily in courses rather than continuously, which is a schedule chosen by convention rather than by any measured exposure.
The comparator that exposes the gap. Several of this site's Khavinson products are injected subcutaneously, which removes the gastric, intestinal and first-pass barriers in a single step. This one is oral only, so it carries the full stack of them, from pepsin to the brush-border peptidases to hepatic first-pass extraction. That difference is not reflected in any dosing guidance anybody publishes, and it should be: an oral course and a subcutaneous course of nominally the same class of material are not comparable exposures, and nobody has measured either.
The exception that matters. If any thyroid hormone survives into the capsule, it does not face this problem at all. T4 and T3 are not peptides and are orally active by design, so the pharmacokinetic argument above protects you from the peptides and not from the contaminant.
What would have to be true, and how you would know it was not
Three predictions. The first is the most useful test on any page in this category, because it is a positive result that would be bad news.
1. TSH should not move. If it falls, the capsule contains hormone. TSH responds to free T4 on a log scale, which makes it the most sensitive available bioassay for thyroid hormone exposure — more sensitive than measuring free T4 itself. A peptide fraction has no mechanism to suppress it, because nothing in a peptidase-labile mixture engages the thyroid hormone receptor. So draw TSH with free T4 before a course and again 6 to 8 weeks later, which is this site's own retest interval after any change to the thyroid axis. A falling TSH with a rising free T4 is not the product working. It is evidence that a thyroid-derived preparation still contains thyroid hormone, and it is the single most informative result anybody could produce about this product.
2. Thyroid antibodies should not change, and are the reason to test before starting. Most hypothyroidism in iodine-replete countries is autoimmune, and thyroid antibodies identify it. This site's guidance is that they are checked annually if positive and that TSH monitoring matters more than repeat titers, which is exactly right here: the antibodies tell you what you have, and TSH tells you where you are. Nothing in a peptide mechanism predicts a change in antibody titer, and a course that changed one would be a genuine surprise worth publishing.
3. The prediction that cuts against the product: free T3 should not rise, and a person who feels better without a change in free T4 or free T3 has learned something about expectation rather than about thyroid function. Fatigue, cold intolerance and weight change are the symptoms this product is bought for, and all 3 are non-specific, highly responsive to attention, and caused far more often by sleep debt, iron deficiency and depression than by the thyroid. Ferritin and a CBC cost less than a course and explain more of that symptom cluster than the thyroid does.
What nobody has tested yet
Four experiments. The first is 1 blood test and it has never been reported by anybody.
1. Nobody has assayed a capsule for T4 and T3. This is the obvious measurement for a thyroid-derived product and it is routine analytical chemistry — liquid chromatography with tandem mass spectrometry, 1 lot, 1 run. It would settle whether the preparation is a peptide product or an unlabeled low-dose hormone product. No vendor publishes it, no independent laboratory has published it, and buyers have no way to find out.
2. Nobody has run the TSH experiment described above. 20 people, TSH and free T4 at baseline and at 6 to 8 weeks, 1 course in between. It would produce both the first human thyroid data on this product and, simultaneously, the contamination screen. Cheap, safe and unrun.
3. Nobody has characterized the mixture. A peptide inventory from a single lot by mass spectrometry would give chain lengths and identifiable sequences, which is the minimum needed to say whether 2 lots are the same product or whether this preparation contains anything short enough for the transporter argument the class rests on.
4. Nobody has looked at the thyroid itself. Ultrasound measures thyroid volume and echotexture, it is inexpensive, it involves no radiation, and it is the direct structural readout for a product claiming to support thyroid tissue. It has never been measured before and after a course of anything in this family.
Thyreogen — its own safety story, not its class's
The class block on this page is written for injectable peptides in general. This product is a capsule made from an endocrine organ, and 3 things about that are its own.
The hormone-contamination risk is the real one and it is not theoretical in structure. If a thyroid-derived preparation carries even a modest amount of T4 or T3, the consequences are the consequences of unmonitored thyroid hormone: palpitations, atrial fibrillation in older people, bone loss over time, and suppression of the body's own axis. Those are not peptide side effects — they are hormone effects, and they would arrive without anyone knowing a hormone had been taken. The people most exposed are those already on levothyroxine, because they are adding an unknown quantity on top of a titrated one. TSH and free T4 at 6 to 8 weeks is the check, and it is not optional on this product the way it is on the others.
Self-treating a thyroid symptom is unusually costly here because the diagnosis is unusually easy. A TSH with a free T4 answers the question in 1 draw. Untreated hypothyroidism does slow damage; untreated hyperthyroidism does faster damage. A capsule with 0 human studies is a poor reason to skip a test that is available in every primary care setting.
What the silence is worth. There are 0 published adverse events for this product, because there have been 0 human trials in which one could have been recorded. That number describes an absence of observation. Combined with an animal-tissue origin and no published composition, the honest summary is that neither the benefit nor the risk of this specific capsule has ever been measured by anyone.
Sources read for this page
- Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M. Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. International Journal of Molecular Sciences 2022;23(14):7733 · PMID 35887081
- Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules 2021;26(22):7053 · PMID 34834147
- Kolchina N, Khavinson V, Linkova N, Yakimov A, Baitin D, Afanasyeva A, Petukhov M. Systematic search for structural motifs of peptide binding to double-stranded DNA. Nucleic Acids Research 2019;47(20):10553–10563 · PMID 31598715
- Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinology Letters 2003;24(3-4):233–240 · PMID 14523363
- Alsulaimani RA, Quinn TJ (independent — not the Khavinson group). The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis. Cerebral Circulation – Cognition and Behavior 2021;2:100012 · PMID 36324709
Thyreogen — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These are short peptide fragments of organ extracts, and the honest starting point is that the mechanism itself is not established in a way that lets anyone predict harm precisely. The proposal is gene-regulatory — short peptides binding DNA and modulating transcription in a tissue-specific way. If that is what they do, the theoretical concern is influencing transcription in tissue you were not aiming at.
- In practice the doses are tiny, the peptides are short, and they are degraded quickly — which is also the argument that they may do very little at all. Those two possibilities are the same uncertainty viewed from opposite ends, and you should hold both.
What has actually been reported
- Decades of Russian clinical use with a strikingly clean tolerability record — injection-site reactions and little else reported.
- That record comes almost entirely from one research school, is largely unreplicated outside it, and safety data from a group with an interest in the outcome is worth less than the same data from a skeptic. This is not an accusation; it is how evidence weighting works.
How to reduce the risk
Same mechanism as the prediction.
- Follow the course printed on the label rather than running continuously. These are the one class in the Vault where a duration is STATED rather than inferred, and it is typically 10–20 days repeated a few times a year. Read the box.
- Run one at a time. They are cheap and it is tempting to stack six. If something changes, a stack of six tells you nothing about which one did it — and given the evidence base, attribution is the entire value of your own experiment.
- Decide your endpoint before you start, and make it a marker or a measurable symptom rather than a feeling. With a compound class this under-evidenced, an unfalsifiable endpoint means you will conclude it worked no matter what happened.
- Buy from a source that publishes third-party testing. Where the molecule itself is uncertain, identity and purity are the only variables you can actually control.
What it does to your bloodwork
A fact about the assay.
- Test the ORGAN, not the peptide. A thymic peptide is judged on immune markers, a pineal one on sleep and IGF-1, a vascular one on lipids and inflammatory markers. There is no assay for the compound itself.
Don't run this if
- Pregnancy — not because of a specific finding, but because nobody has studied it and the mechanism claim is transcriptional.
- Active malignancy, on the same reasoning as any tissue-growth signal: unproven, mechanistically arguable, and not worth finding out.
The honest unknown
- Essentially everything a skeptic would want: independent replication, pharmacokinetics, and whether the oral forms survive digestion at all. Unproven is not the same as ineffective — but here it is a large unproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Thyreogen — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Thyreogen moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
These are short peptide fragments given in microgram amounts and there is no mechanism predicting a specific marker shift. Listing markers here would be padding.
What to do: Test the organ system the bioregulator is aimed at, not a generic panel — that is the only measurement that would tell you anything.
The evidence base here is almost entirely one research group's, largely in Russian, and rarely replicated independently. That is the single most important thing to know before running a course, and it is more useful than any interaction list.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Thyreogen in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Thyreogen
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Thyreogen — frequently asked questions
What is Thyreogen?
Thyreogen (A-2, thyroid peptide bioregulator) is a longevity & bioregulators research compound. Thyroid-derived peptide fraction. Khavinson-school organ peptide extracts. The claim is tissue specificity: a short peptide fraction from one organ is proposed to act on that same organ, restoring its protein synthesis toward a younger pattern by binding regulatory DNA sequences. The mechanism is coherent and the human evidence for it is thin outside the group that proposed it. Note this is a tissue extract, NOT thyroid hormone and not a substitute for it.
Is the full Thyreogen protocol on this page?
The reported research dose is on this page, along with how Thyreogen works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Thyreogen?
Thyreogen has an approximate half-life of Not characterized, which is part of what determines how often it's dosed.
What's the evidence behind Thyreogen?
Current evidence level: Theoretical — Khavinson-school work, largely Russian-language and rarely replicated outside it. Thyreogen is offered for research purposes only and is not an approved medicine.
What Thyreogen is used for
Thyreogen appears under 2 goals in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.